Hot Topics in Blood-Based Cancer Screening

Target Audience

The educational design of this activity addresses identified knowledge and practice gaps among clinicians related to multi-cancer early detection (MCED) screening in primary care practice.

Program Overview

Hot Topics in Blood-Based Multi-Cancer Screening—Volume 3: Updates from ASCO 2026 is a chapter-based CME activity delivering timely, essential insights on MCED testing. The program begins with a foundational overview of MCED, including the science behind blood-based screening, limitations of current screening modalities, and considerations for integration into primary care practice. Dr. Mylynda Massart and Dr. Nima Nabavizadeh then translate data presented at the 2026 ASCO Annual Meeting, including clinical trial and real-world MCED evidence for commercially available and emerging tests and the economics of cancer screening, into practical guidance for primary care. This activity addresses key knowledge and practice gaps related to the rationale for MCED screening, test performance, emerging evidence, and patient selection.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Recognize the limitations of organ-specific cancer screening and describe the clinical rationale for incorporating blood-based MCED testing as a complementary strategy
2. Explain how methylation patterns in circulating cell-free DNA are used to detect cancer signals and identify the tissue of origin
3. Discuss late-breaking and emerging evidence on blood-based MCED testing from ASCO 2026
4. Develop a practical approach to MCED screening in primary care, including patient selection, result communication, and guidance on the changing reimbursement and regulatory landscape

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Reciprocity Statement

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 70% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mylynda B. Massart, MD, PhD: Consulting Fees: GRAIL, Inc.

Nima Nabavizadeh, MD: Consulting Fees: GRAIL, Inc.; Speakers’ Bureau: Roche Diagnostics

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.